RxDoctor Payments Data

Karl Becker, MD

Ophthalmology · Chicago, ILNPI 1114471745

Payments from drug & device makers

$3,085in general payments, 2019–2025

Across 78 payments — averaging $39.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Regeneron Healthcare Solutions, Inc.$460
  • AbbVie$364
  • Eyepoint US, Inc.$186
  • Glaukos Corporation$148
  • Optos, Inc.$129
  • plus $663 from 13 others

What the payments were for

  • Food & beverage$2,95696%
  • Entertainment$1294%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,085 in reported general payments places this provider in the 65th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,152,211
Medicare patients
600
Services billed
17,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine26$19,421
Cyclosporine24$13,808
Prednisolone Acetate266$10,594
LumiganBimatoprost12$6,818
Ketorolac Tromethamine219$5,375
Difluprednate37$4,097
Latanoprost253$2,963
Mycophenolate Mofetil18$2,014
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat105$1,992
Ofloxacin142$1,985
Dorzolamide-TimololDorzolamide/Timolol/Pf15$1,784
MoxifloxacinMoxifloxacin Hcl42$951
Timolol Maleate79$758
Dorzolamide Hcl17$560
Brimonidine Tartrate33$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$364$26,23938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →